cellvie Inc.

DGAP-News: Harvard spin-off CELLVIE closes $5M seed round in pursuit of a new treatment modality: therapeutic mitochondria transfer

Retrieved on: 
Monday, January 25, 2021
Mitochondria, Cellular respiration, Mitochondrion, cellvie Inc., KIZOO

Harvard spin-off CELLVIE closes $5M seed round in pursuit of a new treatment modality: therapeutic mitochondria transfer

Key Points: 
  • Harvard spin-off CELLVIE closes $5M seed round in pursuit of a new treatment modality: therapeutic mitochondria transfer
    The issuer is solely responsible for the content of this announcement.
  • "That is why we turned to introducing healthy, viable mitochondria into cells where these organelles are impaired.
  • The potential of Therapeutic Mitochondria Transfer was recently demonstrated in a clinical investigation at Boston Children's Hospital.
  • Founded in the US and headquartered close to Zrich, Switzerland, cellvie is developing medicines from cells, leveraging the therapeutic potential of mitochondria.